logo-wfh
logo-gmh

Home

About the WFH Treatment Guidelines

The World Federation of Hemophilia (WFH) publishes internationally recognized guidelines to support the care and treatment of people with inherited bleeding disorders.

WFH Living Guidelines for the Management of Hemophilia

This hub is home to the WFH’s Living Guidelines for the Management of Hemophilia, which are
continuously updated in response to new evidence, therapies, and evolving clinical practice. As a “living” resource, these guidelines evolve over time to reflect the most current evidence.

The living model also includes:

  • Regular updates to recommendations as new evidence becomes available
  • Transparency on methods, evidence sources, and decision processes
  • Practice tools and resources to support implementation in clinical care

     

von Willebrand Disease Guidelines

The Guidelines Hub also hosts WFH guidelines for the
treatment of von Willebrand disease (VWD):

Overview of the WFH Treatment Guidelines

Glenn Pierce, MD, PhD
WFH Vice President, Medical
The World Federation of Hemophilia has published the third edition of Guidelines for the Management of Hemophilia. Developed through a formal evidence-informed and consensus-based methodology involving multidisciplinary healthcare professionals (HCPs) and well-informed people with hemophilia (PWH), these guidelines offer 340 practical recommendations on managing care for PWH. The guidance provides a framework for the development of a comprehensive healthcare system supporting PWH, including advocacy and patient empowerment.

Browse by chapter

Principles of care

Chapter 01
Alok Srivastava
MD, FRACP, FRCPA, FRCP
Professor of Medicine Department of Haematology Head, Centre for Stem Cell Research Christian Medical College
Vellore, India

Comprehensive care of hemophilia

Chapter 02
Kate Khair
PhD
Director of Research, Haemnet, London Centre for Outcomes and Experience Research in Children's Health, Illness and Disability (ORCHID), Great Ormond Street Hospital for Children
London, UK

Genetic assessment

Chapter 04
Megan Sutherland
PhD
Clinical Scientist Genomic Diagnostics Laboratory Manchester Center for Genomic Medicine Manchester University NHS Foundation Trust Saint Mary's Hospital
Manchester, United Kingdom

Hemostatic agents

Chapter 05
Steven W. Pipe
MD
Professor of Pediatrics and Pathology Laurence A. Boxer Research Professor of Pediatrics and Communicable Diseases Pediatric Director, Hemophilia and Coagulation Disorders Program Director, Special Coagulation Laboratory University of Michigan
Ann Arbor, Michigan, United States

Prophylaxis in hemophilia

Chapter 06
Manuel Carcao
MD, MSc
Staff Haematologist Co-Director, Hemophilia Clinic Hospital for Sick Children Professor of Paediatrics University of Toronto
Toronto, Ontario, Canada

Treatment of specific hemorrhages

Chapter 07
Johnny Mahlangu
BSc, MBBCh, MMed, FCPath
Clinical Haematologist, Charlotte Maxeke Johannesburg Academic Hospital and Department of Molecular Medicine and Haematology Professor in Haematology, Faculty of the Health Sciences University of the Witwatersrand and National Health Laboratory Service
Johannesburg, South Africa

Inhibitors to clotting factor

Chapter 08
Margaret V. Ragni
MD, MPH
Professor of Medicine and Clinical Translational Science Department of Medicine, Division Hematology/Oncology University of Pittsburgh Medical Center Director, Hemophilia Center of Western PA
Pittsburgh, PA

Specific management issues

Chapter 09
Jerzy Windyga
PhD, MD
Department of Hemostasis Disorders and Internal Medicine IHIT Instytut Hematologii I Transfuzjologii
Warsaw, Poland

Outcome assessment

Chapter 11
Pradeep M. Poonnoose
MD
Professor, Department of Orthopaedics Christian Medical College
Vellore, India

Methodology

Chapter 12
Sandra Zelman Lewis
PhD
President, EBQ Consulting, LLC Evidence-based Guidelines and Quality Improvement
Northbrook, Illinois, USA

These materials are derived from the WFH Guidelines for the Management of Hemophilia, 3rd edition [© 2020 World Federation of Hemophilia. Haemophilia © 2020 John Wiley & Sons Ltd]

For the full set of recommendations, please refer to the full WFH Treatment Guidelines, available here.

For questions, contact treatmentguidelines@wfh.org

These educational materials were made possible through the support of the Hemophilia Alliance. 

WFH

Events

Useful Links

For questions, contact treatmentguidelines@wfh.org

© World Federation of Hemophilia 2025